Taiwan’s government has taken several initiatives in recent years to promote the biotech industry and drug development. Taiwan has a large pool of bioscientists and high-tech talent, as well as an impressive medical research base.As a result, Taiwan’s biotech industry is on a strong upward path and is increasingly becoming an attractive destination for outsourcing drug development. A key measure was the replacement in 2000 of local registration trial requirements with bridging study evaluations that follow international standards. This prompted leading pharmaceutical companies to include Taiwan in their development plans for early phase clinical trials.

​

Dr Christophe Tournerie, CEO ClinActis Pte Ltd, commented: “ClinActis is pursuing its development plan in the region, and the expansion in Taiwan is a new milestone for the company. With its presence in Taiwan, ClinActis is able to offer sponsors state-of-the-art clinical research services in this country which offers strong prospects to the pharmaceutical industry“.

​

ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore. Our goal is to become the reference CRO specialized in conducting clinical research in Asia Pacific, offering state of the art quality services, with cost effective solutions. We have 29 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs, of which 23 years experience is in Asia Pacific. Our therapeutic experience includes cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, Respiratory and Nutrition. Our services include consultancy on product development strategy in Asia Pacific, Clinical project management, Site management, Clinical monitoring, Clinical research and ICH GCP training, and Temporary clinical staffing.

​

To know more, visit us at www.clinactis.com